Localized and metastatic myxoid/round cell liposarcoma: Clinical and molecular observations

Cancer

Volumn 119, Issue 10, 2013, Pages 1868-1877

  Hoffman, Aviad ^a   Ghadimi, Markus P H ^a,b   Demicco, Elizabeth G ^a   Creighton, Chad J ^c   Torres, Keila ^a   Colombo, Chiara ^a   Peng, Tingsheng ^a   Lusby, Kristelle ^a   Ingram, Davis ^a   Hornick, Jason L ^d   Wang, Wei Lie ^a   Ravi, Vinod ^a   Lazar, Alexander J ^a   Lev, Dina ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

molecular biomarkers; myxoid liposarcoma; outcome; round cell liposarcoma; therapeutic targets; tissue microarray

Indexed keywords

ADIPOPHILIN; CHEMOKINE RECEPTOR CXCR4; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA; PLATELET DERIVED GROWTH FACTOR BETA; PROTEIN P53; PROTEIN TYROSINE KINASE; TRABECTEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AXL GENE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS RESECTION; MYXOSARCOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIPOSARCOMA; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84877586101     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27847     Document Type: Article

References (30)

1. Weiss SW, Goldblum JR,. Liposarcoma. In:, Weiss SW, Goldblum JR, Enzinger FM, eds. Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St. Louis, MO: Mosby; 2001: 641-693.
2. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001; 7: 3977-3987.
3. Knight JC, Renwick PJ, Dal Cin P, Van den Berghe H, Fletcher CD,. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995; 55: 24-27.
4. Panagopoulos I, Mandahl N, Mitelman F, Aman P,. Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). Oncogene. 1995; 11: 1133-1137.
5. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene. 2000; 19: 6015-6022.
6. Adelmant G, Gilbert JD, Freytag SO,. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J Biol Chem. 1998; 273: 15574-15581.
7. Fletcher CDM, ed. Pathology and Genetics of Soft Tissue and Bone: World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2002.
8. Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG,. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996; 77: 1450-1458.
9. Haniball J, Sumathi VP, Kindblom LG, et al. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma [serial online]. Sarcoma. 2011; 2011: 538085.
10. ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, Bastiaannet E, Suurmeijer AJ,. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol. 2007; 14: 222-229.
11. Moreau LC, Turcotte R, Ferguson P, et al. Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Canadian Orthopaedic Oncology Society (CANOOS). Ann Surg Oncol. 2012; 19: 1081-1088.
12. Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007; 109: 2522-2531.
13. Nishida Y, Tsukushi S, Nakashima H, Ishiguro N,. Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall. Clin Orthop Relat Res. 2010; 468: 3041-3046.
14. Dei Tos AP, Piccinin S, Doglioni C, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997; 151: 1531-1539.
15. Cheng H, Dodge J, Mehl E, et al. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol. 2009; 40: 1244-1251.
16. Demicco EG, Torres KE, Ghadimi MP, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012; 25: 212-221.
17. Guadagnolo BA, Zagars GK, Ballo MT, et al. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 760-765.
18. Yee KS, Grochola L, Hamilton G, et al. A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res. 2012; 72: 2206-2217.
19. Katz D, Boonsirikamchai P, Choi H, et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma [serial online]. Clin Sarcoma Res. 2012; 2: 2.
20. Spillane AJ, Fisher C, Thomas JM,. Myxoid liposarcoma-the frequency and the natural history of nonpulmonary soft tissue metastases. Ann Surg Oncol. 1999; 6: 389-394.
21. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW,. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res. 1998; 294: 309-321.
22. Zhang GY, Ahmed N, Riley C, et al. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2005; 92: 113-119.
23. Kim RH, Li BD, Chu QD,. The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma[serial online]. Sarcoma. 2011; 2011: 593708.
24. Muller A, Homey B, Soto B, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410: 50-56.
25. Murakami T, Cardones AR, Hwang ST,. Chemokine receptors and melanoma metastasis. J Dermatol Sci. 2004; 36: 71-78.
26. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000; 6: 50-56.
27. Smith TA, Goldblum JR,. Immunohistochemical analysis of p53 protein in myxoid/round cell liposarcomas of the extremities. Appl Immunohistochem. 1996; 4: 228-234.
28. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S,. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther. 2011; 10: 1763-1773.
29. Olofsson A, Willen H, Goransson M, et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol. 2004; 25: 1349-1355.
30. Catena R, Luis-Ravelo D, Anton I, et al. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res. 2011; 71: 164-174.